TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11421877
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.d. plus amoxicillin 1 g b.d. and tinidazole 500 mg b.d. (RAT group)
Study: 11421877
Drug: Maastricht triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maastricht triple therapy
Study: 9431863
Drug: Dobutamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (1 micromol/l, 15 min) after hypoxia-reoxygenation
Study: 8480740
Drug: Aspartame (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (15 mg/kg)
Study: 26574828
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group).
Study: 23430759
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of genotypes associated with an anti-inflammatory profile
Study: 18094222
Drug: Low-dose ATRA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ATRA (1 mg/kg/day)
Study: 10473232
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg p.o. od for 7 days
Study: 10473232
Drug: Chloramphenicol 2-3
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol 2-3 g p.o. od in four divided doses for 14 days
Study: 7048518
Drug: Concurrent chemo/hormonotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemo/hormonotherapy
Study: 24490628
Drug: VL +
Normalized name: VL-2397
DrugBank: VL-2397 (DB17796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VL + local anesthesia without analgesics
Study: 24490628
Drug: VL +
Normalized name: VL-2397
DrugBank: VL-2397 (DB17796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VL + local anesthesia + analgesics
Study: 21425346
Drug: Reminiscence group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence group therapy (three sessions per week for 24 weeks)
Study: 21425346
Drug: Weekly individual
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly individual supportive interviews (control group)
Study: 11315126
Drug: Crystalloid cardioplegia
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid cardioplegia + L-arginine
Study: 29698966
Drug: Diamine oxidase
Normalized name: Diamine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamine oxidase (DAO) supplementation, 1 capsule b.i.d., 15 min before a meal for 30 days
Study: 26364551
Drug: AZD2014 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2014 (50 mg twice daily)
Study: 21306238
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg once daily)
Study: 23097413
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma gel (PRPG)
Study: 20942866
Drug: Concurrent arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent arm (Arm C) - R-CHOP: 6 R treatments (375 mg/m²) 2 days prior to each cycle of CHOP
Study: 20942866
Drug: Sequential arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential arm (Arm S) - R-CHOP: 6 weekly R treatments (375 mg/m²) following six cycles of CHOP
Study: 12744985
Drug: Preventive medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive medicine curriculum (case-based approach)
Study: 8791949
Drug: omeprazole 500
Normalized name: amoxicillin/clarithromycin/omeprazole 500 mg-500 mg-20 mg oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 500 mg q.d.s. plus amoxycillin 20 mg b.d.
Study: 3720571
Drug: Cholestyramine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (24 g/day)
Study: 30558079
Drug: Bosinji granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosinji granule (2.5 g, 1.523 g of Bosinji extract)
Study: 15295219
Drug: Palivizumab 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab 15 mg/kg
Study: 1728190
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy (15 sessions)
Study: 1728190
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (medication withdrawn at 16 or 24 weeks)
Study: 1728190
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (24-week duration)
Study: 28433518
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 10 mg/kg
Study: 29505147
Drug: Parenteral Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Protein Calculator (PPC)
Study: 24281905
Drug: n‐3 FA‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 FA‐enriched oral nutritional supplement (Supportan, 200 ml twice daily) providing 2.0 g EPA and 1.0 g DHA per day
Study: 22128200
Drug: Dienogest 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 0.5 mg daily
Study: 22128200
Drug: Dienogest 1
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest 1 mg daily
Study: 22128200
Drug: Dienogest 2
Normalized name: dienogest 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 2 mg daily
Study: 22128200
Drug: Dienogest 3
Normalized name: dienogest 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 3 mg daily
Study: 7479200
Drug: Piperacillin 4
Normalized name: piperacillin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4 g plus tazobactam 500 mg by intravenous intermittent infusion every 8 hours
Study: 2320708
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg q8h
Study: 2320708
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg q12h
Study: 2320708
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg q8h
Study: 7367815
Drug: Anticholinergic drug
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drug therapy
Study: 10193254
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 10 ppm
Study: 427822
Drug: oral L‐PAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral L‐PAM
Study: 31490342
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Study: 31490342
Drug: Participants reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants reporting stimulant use
Study: 31490342
Drug: Participants reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants reporting other nonalcohol drug use
Study: 1841788
Drug: bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate 400 mg/daily
Study: 1841788
Drug: nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 30 mg/daily
Study: 6195483
Drug: Prizidilol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol 200 mg once daily
Study: 6195483
Drug: Prizidilol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol 400 mg once daily
Study: 25239172
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of saline water (placebo)
Study: 22206591
Drug: Group reminiscence
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group reminiscence therapy combined with health education for 6 weeks
Study: 11981083
Drug: Theophylline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (4 mg/kg bolus and 0.25 mg/kg/h continuous infusion for up to 96 h)
Study: 10619543
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (8-week program including progressive muscle relaxation, guided imagery, self-instruction training, study and test-taking skills)
Study: 7552768
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (0.05 mg/kg)
Study: 27904156
Drug: Benidipine plus
Normalized name: benidipine
DrugBank: Benidipine (DB09231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine plus β-blocker
Study: 19048338
Drug: Treated groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated groups (various treatments across groups)
Study: 12799209
Drug: Lenercept 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenercept 0.125 mg/kg
Study: 7699494
Drug: 1-minute increment
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-minute increment intervals of midazolam (1 mg)
Study: 2698569
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg slow-release gallopamil (200 mg/day in two divided doses for 7 days)
Study: 16306832
Drug: Positive selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive selective nerve root injection (SNI) results
Study: 16306832
Drug: Negative selective
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative selective nerve root injection (SNI) results
Study: 12088919
Drug: 0.17 mg
Normalized name: clonidine 0.17 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.17 mg GH/day (starting dose), titrated by steps of 0.17 mg GH/day every 6-8 weeks, maintenance median GH dose of 0.33 mg/day in males and 0.83 mg/day in females
Study: 10206440
Drug: Hypoosmolality induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoosmolality induced by intravenous administration of desmopressin, liberal ingestion of water, and infusion of hypotonic (0.45%) saline solution
Study: 2514824
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion starting at 2 mU/min up to 16 mU/min during the second stage of labour
Study: 2514824
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion during the second stage of labour
Study: 327432
Drug: Progressive relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive relaxation treatment
Study: 31931444
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2) plus cisplatin (80 mg/m2) (arm A)
Study: 31931444
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m2) plus carboplatin (AUC 6) (arm B)
Study: 31124931
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (CD) 750 mg/d
Study: 19151302
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine with 2% lidocaine (100 mg + 400 mg)
Study: 19151302
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine (300 mg)
Study: 19151302
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine with 2% lidocaine (150 mg + 400 mg)
Study: 25130281
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg once daily
Study: 25440809
Drug: Rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (40 mg on admission followed by 20 mg/d; statin group, n = 252)
Study: 20168272
Drug: Modified Early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Early Treatment Diabetic Retinopathy Study laser photocoagulation
Study: 2198075
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (VCMP/VBAP)
Study: 6638418
Drug: Endobronchial double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial double lumen tube for one-lung ventilation with intravenous anaesthesia and muscular relaxation
Study: 23873901
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with intravitreal ranibizumab and topical ketorolac (group 1)
Study: 19787290
Drug: pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (30 mg)
Study: 19787290
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy (control)
Study: 15370932
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/d) + Relapse Prevention therapy
Study: 15370932
Drug: Naltrexone (placebo)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (placebo) + Drug Counseling
Study: 11092518
Drug: Soy breakfast
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy breakfast cereal (providing 36 g/d soy protein and 168 mg/d isoflavones)
Study: 3082694
Drug: Flunisolide nasal
Normalized name: flunisolide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide nasal spray plus terfenadine tablets (50 mcg flunisolide to each nostril twice daily and 60 mg terfenadine twice daily)
Study: 3082694
Drug: Terfenadine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine alone (60 mg terfenadine twice daily)
Study: 3272745
Drug: Bupivacaine (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.25% epidural, 6 to 12 ml/hour)
Study: 3272745
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg intramuscularly, no more frequently than every 4 hours)
Study: 20506391
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg, 2 subcutaneous injections at 7-day intervals)
Study: 18402744
Drug: KS palm
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KS palm grip (26173 ML)
Study: 9059137
Drug: Prednisolone at
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone at 2.00 am (5 or 7.5 mg daily)
Study: 2874527
Drug: Cysteamine (somatostatin-depleting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine (somatostatin-depleting agent) at maximum tolerated dosage for 2 weeks
Study: 29982534
Drug: Fructans (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructans (6 g/d)
Study: 15804155
Drug: Increased flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased flow through the CDI sensor to approximately 400 mL/min
Study: 12424162
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg per day for 14 days)
Study: 9054781
Drug: Assertive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive community treatment alone
Study: 9090733
Drug: Assertive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive community treatment with community workers
Study: 10899490
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined HRT (ccHRT) containing estradiol (2 mg/d) + estriol (1 mg/d) + norethindrone acetate (1 mg/d)
Study: 9035017
Drug: Etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 200 mg qid
Study: 7705193
Drug: Washout period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washout period (2 months after discontinuation of Goshajinkigan)
Study: 3588662
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg bromocriptine
Study: 16478755
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg bromocriptine
Study: 3588662
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg bromocriptine
Study: 21330907
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel
Study: 25935783
Drug: TrimoSan gel
Normalized name: Triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TrimoSan gel
Study: 23370697
Drug: Inhalation during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation during the lift
Study: 18071341
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet plus sibutramine (10 mg per day)
Study: 16863011
Drug: Single-dose sertaconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose sertaconazole vaginal tablet (500 mg)
Study: 16863011
Drug: Conventional 3-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 3-dose econazole vaginal tablet (150 mg)
Study: 10673309
Drug: Interferon-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2b plus 200 mg ketoprofen twice a day
Study: 2719462
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of ciprofloxacin twice daily for 5 days
Study: 2719462
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of ciprofloxacin twice daily plus 300 mg of rifampin twice daily for 21 days
Study: 141237
Drug: alcuroium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: alcuroium 0.3 mg/kg
Study: 141237
Drug: gallamine 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallamine 1.8 mg/kg
Study: 141237
Drug: suxamethonium 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 0.8 mg/kg
Study: 31279278
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage (1g/100ml curry) - single meal or multiple meals
Study: 28355706
Drug: Rock salt
Normalized name: Nivea Men Rock Salts Body Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rock salt aerosol therapy
Study: 12464165
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (control group)
Study: 25091666
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of Rotarix vaccine (n=45)
Study: 19411529
Drug: Survey respondents
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Survey respondents comparing oral health to arthritis
Study: 11810416
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen plus progestogen (E‐P)
Study: 9180950
Drug: 8OU of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8OU of BoTox injected in four quadrants (1 ml in each quadrant‐20 U/ml) (n = 8)
Study: 9180950
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution as placebo injected in the same way (n = 5)
Study: 1827020
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg twice daily)
Study: 31521613
Drug: CHMI-derived parasites
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHMI-derived parasites from volunteer groups receiving different PfSPZ dose and route
Study: 10929273
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 mg daily
Study: 10929273
Drug: Low-dose pimozide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pimozide 2 mg daily
Study: 10929273
Drug: Low-dose pimozide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pimozide 4 mg daily
Study: 6465511
Drug: Urapidil (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (0.6 mg/kg before induction, 0.4 mg/kg +/- 0.2 mg/kg before termination)
Study: 25208756
Drug: Albiglutide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide (30 mg once a week, n=504)
Study: 25208756
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (10 U once a day, n=241)
Study: 1662796
Drug: M37 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M37 vaccine 10(4) PFU
Study: 4031977
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy without BCNU
Study: 23762354
Drug: Gastric irrigation
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric irrigation with 2 L saline solution before ESD
Study: 23762354
Drug: Gastric irrigation
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric irrigation with saline solution
Study: 19115593
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of HES 130/0.4 (Gr II : n = 61)
Study: 14562117
Drug: chemotherapy (hydroxyurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy (hydroxyurea (HU))
Study: 14562117
Drug: chemotherapy (busulfan)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy (busulfan)
Study: 25457928
Drug: Telephone cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone cognitive-behavioral therapy (TCBT)
Study: 12412822
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray (2.5, 5.0, or 10 mg)
Study: 17883519
Drug: Zolmitriptan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan (all formulations)
Study: 12412822
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray vs oral formulations
Study: 2225364
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of adenosine (80 micrograms/min or more)
Study: 2225364
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of adenosine (140 micrograms/kg/min)
Study: 2225364
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of adenosine (up to 240 micrograms/min)
Study: 25833163
Drug: Hib-MenAC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-MenAC vaccine